148 related articles for article (PubMed ID: 6819250)
1. Comparison of the effectiveness of several formulations of sodium valproate: tablets, enteric-coated capsules, solutions and rectal capsules.
Battino D; Biraghi M; Cusi C; Nespolo A; Avanzini G
Ital J Neurol Sci; 1982 Oct; 3(3):197-200. PubMed ID: 6819250
[TBL] [Abstract][Full Text] [Related]
2. Comparative steady state serum levels of valproic acid administered as two different formulations--Deprakine and Orfiril.
Johannessen SI; Henriksen O
Acta Neurol Scand; 1979 Dec; 60(6):371-4. PubMed ID: 121513
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability of sodium valproate suppositories during repeated administration at steady state in epileptic children.
Issakainen J; Bourgeois BF
Eur J Pediatr; 1987 Jul; 146(4):404-7. PubMed ID: 3115782
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal tolerance of divalproex sodium.
Wilder BJ; Karas BJ; Penry JK; Asconape J
Neurology; 1983 Jun; 33(6):808-11. PubMed ID: 6405304
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.
Bialer M; Hussein Z; Dubrovsky J; Raz I; Abramsky O
Isr J Med Sci; 1984 Jan; 20(1):46-9. PubMed ID: 6421770
[TBL] [Abstract][Full Text] [Related]
6. Single-dose kinetics and bioavailability of sodium-hydrogen divalproate.
Anderson P; Elwin CE
Clin Neuropharmacol; 1985; 8(2):156-64. PubMed ID: 3924399
[TBL] [Abstract][Full Text] [Related]
7. Rectal administration of sodium valproate in children.
Scanabissi E; Dal Pozzo D; Franzoni E; Galloni C; Mengoli G; Calivà R
Ital J Neurol Sci; 1984 Jun; 5(2):189-93. PubMed ID: 6432726
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of enteric-coated valproic acid.
Albright PS; Bruni J; Suria D
Ther Drug Monit; 1984; 6(1):21-3. PubMed ID: 6424275
[TBL] [Abstract][Full Text] [Related]
9. Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle).
Carrigan PJ; Brinker DR; Cavanaugh JH; Lamm JE; Cloyd JC
J Clin Pharmacol; 1990 Aug; 30(8):743-7. PubMed ID: 2119396
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pharmacokinetic observations on sodium valproate - a 5-year follow-up study in 100 children with epilepsy.
Henriksen O; Johannessen SI
Acta Neurol Scand; 1982 May; 65(5):504-23. PubMed ID: 6810648
[TBL] [Abstract][Full Text] [Related]
11. Effect of food on the serum concentration profile of enteric-coated valproic acid.
Fischer JH; Barr AN; Paloucek FP; Dorociak JV; Spunt AL
Neurology; 1988 Aug; 38(8):1319-22. PubMed ID: 3135514
[TBL] [Abstract][Full Text] [Related]
12. Chrono impact versus enteric coated valproate in Thai epileptic patients.
Towanabut S; Tiemkao S; Thammasupapong S; Kijjarak R; Arayawichanon A; Poungvarin N; Sirimaharaj S; Chaisewikul R; Asawavichenjinda T; Maneesuk S; Silpakit O
J Med Assoc Thai; 2005 Nov; 88(11):1651-9. PubMed ID: 16471115
[TBL] [Abstract][Full Text] [Related]
13. Successful initiation of combined therapy with valproate sodium injection and divalproex sodium extended-release tablets in the epilepsy monitoring unit.
Boggs JG; Preis K
Epilepsia; 2005 Jun; 46(6):949-51. PubMed ID: 15946337
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet.
Garikipati V; Toops DS; Fang Q
Curr Med Res Opin; 2008 Jul; 24(7):1869-76. PubMed ID: 18593524
[TBL] [Abstract][Full Text] [Related]
15. Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers.
Roberts D; Easter D; O'Bryan-Tear G
Biopharm Drug Dispos; 1996 Mar; 17(2):175-82. PubMed ID: 8907724
[TBL] [Abstract][Full Text] [Related]
16. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
Wangemann M; Retzow A; Vens-Cappell B
Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical evaluation of hollow type suppositories. V. Preparation of valproic acid suppository and rectal absorption of valproic acid in rabbits.
Watanabe Y; Tone Y; Nishihara S; Matsumoto M
J Pharmacobiodyn; 1986 Dec; 9(12):953-61. PubMed ID: 3106614
[TBL] [Abstract][Full Text] [Related]
19. Treatment of childhood epilepsy with rectal valproate: case reports and pharmacokinetic study.
Kanazawa O; Sengoku A; Kawai I
Brain Dev; 1987; 9(6):615-20. PubMed ID: 3128135
[TBL] [Abstract][Full Text] [Related]
20. [Sodium valproate (Na VPa) monotherapy in childhood epilepsy ].
Dulac O; Steru D; Rey E; Arthuis M
Arch Fr Pediatr; 1982; 39(6):347-52. PubMed ID: 6812534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
